Increase in diazepam binding inhibitor-like immunoreactivity (51-70) in Huntington's disease.
In Huntington's disease (HD), reduction in striatal GABA is one of the most striking abnormalities and alterations in benzodiazepine receptors, which are allosterically linked to the GABAA receptor, have also been reported. Diazepam binding inhibitor (DBI), recently isolated from rat and human brain, has been proposed as an endogenous ligand at the benzodiazepine receptor. The content of DBI-like immunoreactivity(51-70) (DBI-IR(51-70), has therefore been compared in control postmortem human brains and in HD brains (matched for age, sex and post-mortem delay), using a specific radioimmunoassay. DBI-IR(51-70) was more than 1.5-fold increased in the putamen, caudate, globus pallidus and nucleus accumbens of HD brains compared to the control group (P less than 0.001). Gel filtration chromatography showed similar elution profiles of the peptide in both control and HD extracts, thus providing no evidence for a change in the nature of the peptide itself.
Ball
J A
JA
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.
Burnet
P W
PW
Bretherton-Watt
D
D
Bloom
S R
SR
D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000378:metabolism*; D026261:Diazepam Binding Inhibitor; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009479:Neuropeptides / Q000378:metabolism*; D011863:Radioimmunoassay; D011963:Receptors, GABA-A / Q000378:metabolism*
D026261:Diazepam Binding Inhibitor; D009479:Neuropeptides; D011963:Receptors, GABA-A